Share this page with your friends and co-workers with the linking options above.
QBIO Stock Alert
Company Name: Q BioMed Inc.
Stock Symbol: QBIO Company Website: www.qbiomed.com
Trading at approx $3.67 Per Share (03/24/2016)
About Q BioMed Inc.:
Q BioMed Inc. is a biomedical acceleration and development company focused on acquiring companies and biomedical assets in clinical stage or and near revenue development. The company is dedicated to providing these target companies strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.
Here are some words by Denis Corin, CEO of QBioMed in a recent interview this week:
“In the last quarter of 2015, we entered into an exclusive License and Purchase Option Agreement with Mannin Research Inc. whereby we were granted a worldwide, exclusive license, with the option to acquire their platform assets for Glaucoma and other indications. The Mannin IP and technology platform is initially focused on developing a first-in-class eye drop treatment for glaucoma. The technology platform may be expanded in scope beyond Glaucoma as well as beyond ophthalmological uses and may include cystic kidney disease and others.
This is an area of therapy that urgently needs a new offering. No new drugs in this particular indication have been successfully brought to this market for over 20 years.
The global market for Glaucoma therapeutics is one of the largest segments of the $23 billion global ophthalmology market. There are 60 million people worldwide suffering from Glaucoma. It is projected that the total population suffering from Glaucoma will grow to 80 million by 2020 (W.H.O 2010), so there is an acute need for this type of drug in a very lucrative market. Our lead candidate, MAN-01, will address this market as a first-in-class drug that treats abnormal vessels within the eye, thereby treating Glaucoma at its root causes.
There is no cure for Glaucoma and new therapeutics are highly sought after. Current therapies and surgical procedures are not optimally effective, are painful and not well tolerated by patients.
Together with Mannin, we are developing a unique molecule in the form of an easy-to-administer eye drop, designed to repair the normal flow of fluid in the eye and resulting in the reduction of intraocular pressure (IOP), one of the main causes of Glaucoma. Our platform is both unique and first-in-class and we are the only drug company targeting this method of action.
Given the large 23 Billion dollar ophthalmology market and the acute need for these types of drugs, we believe there is a substantial opportunity here. In addition, a deep pipeline of novel therapeutics can be developed from this research platform, developed and lead by Dr. Quaggin, which would treat a spectrum of vascular diseases including Cystic Kidney disease.
So to sum up, while this is an earlier stage pre-clinical asset, we see tremendous opportunity here and look forward to building value in it as we advance.” Source: Visit http://qbiomed.com/newsevents/ to read the full interview and other recent press releases
Disclaimer: StockPicksNYC (Baran Giresunluoglu) is not a registered investment advisor or a registered securities broker dealer. Any information contained in our website or email newsletter should be viewed as commercial entertainment and is not investment advice. We strongly advise that you don’t make any investment decisions solely based on the information provided in this website or newsletter. If you choose to invest in any companies mentioned in our research then consult with a licensed financial advisor before taking any action. We will do our very best to provide you with stocks to watch but we can NOT guarantee anything. Any individual who chooses to invest in any securities, we advise you should do so with caution. Investing in Stocks carries a high degree of risk and you may a lose some or all of the money that you have invested. I encourage everyone to do their own research if they choose to invest in any company. We release our stock alerts based on company news, profile, fundamental analysis , and other factors. I reserve the right to buy and sell shares after I initiate coverage on the company without any additional disclosure. The content provided from this website should only be viewed as commercial entertainment and should not be viewed as actual investing advice. Please keep in mind that past performance does not guarantee future results. Stock Picks NYC ( Baran Giresunluoglu ) will not be liable for any incidental, indirect, punitive, actual, consequential, speical, exemplary, or other damages including loss of money, pain and suffering. StockPicksNYC tries to provide accurate information by using public resources but cannot and does not guarantee the accurateness and completeness of statements made regarding the companies mentioned. Individuals should go as far as assuming that all information about profiled companies is untrustworthy unless verified by their own independent research. Please Keep in mind that the information provided by this website may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company’s actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company’s products, the company’s ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. If StockpicksNYC receives compensation to profile a company, then StockPicksNYC will fully disclose it in the disclaimer. StockPicksNYC was compensated six thousand dollars via wire transfer to bring public awareness for q bioMed inc by a third party. The content provided from this website is intended to be viewed as commercial entertainment and should NOT be viewed as investment advice. We strongly encourage that you do your own research and before making any investments in any securities.